Remission makes its way to rheumatology 英文参考文献.docVIP

Sokka and M?kinen Arthritis Research Therapy 2010,12:129 /content/12/4/129 EDITORIAL Remission makes its way to rheumatology Tuulikki Sokka* and Heidi M?kinen 1 2 See related research by Saber et al., /content/12/3/R94 68% met the DAS28 remission criter e ? ndings indicated that a strategy of ‘tight control’ appeared to be more important than a speci? c agent in the control of RA. Subsequent studies con? rmed the importance of a ‘tight control’ strategy directed to ‘treat to target’ accord- Abstract Remission was a rare event, even in the most advanced rheumatology clinics, until recent times. However, in the early 1990s, it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial, which can be considered the beginning of remission’s way to rheumatology. In addition to remission in patients with rheumatoid arthritis, remission in patients with psoriatic arthritis is now being studied, although remission criteria for psoriatic arthritis have yet to be de?ned. Better treatment results with more active treatment strategies and availability of biologic agents motivate rheumatologists to monitor their patients as part of usual rheumatology care. ing to a quantitative go e TICORA (Tight Control of Rheumatoid Arthritis) trial reported a remission rate of 65% using conventional DMARDs. In the CIMESTRA (Cyclosporine, Methotrexate, Steroid in Rheumatoid Arthritis) trial, remission rates were 59% and 54% for DAS28 remission and 41% and 35% for American College of Rheumatology (ACR) remission at 2 years in the combination and monotherapy arms, respectively [4]. In the BeSt (Behandelstrategie?n voor Reumatoide Artritis) study of treatment strategies for RA, 38% to 46% of patients in the four arms were in remission at the end of intervention [5]. At this time, remission